SRA Gene Knockout Protects against Diet-induced Obesity and Improves Glucose Tolerance*

Received for publication, March 12, 2014 Published, JBC Papers in Press, March 27, 2014, DOI 10.1074/jbc.M114.564658

Shannon Liu†, Liang Sheng§†, Hongzhi Miao§, Thomas L. Saunders§, Ormond A. MacDougald†§, Ronald J. Koenig†‡, and Bin Xu†§

From the †Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, the Departments of §Molecular and Integrative Physiology and ¶Pathology, and the ‡Division of Molecular Medicine and Genetics, Transgenic Animal Model Core, University of Michigan Medical Center, Ann Arbor, Michigan 48109-5678

We have recently shown that the non-coding RNA, steroid receptor RNA activator (SRA), functions as a transcriptional coactivator of PPARγ and promotes adipocyte differentiation in vitro. To assess SRA function in vivo, we have generated a whole mouse Sra1 gene knock-out (SRA−/−). Here, we show that the Sra1 gene is an important regulator of adipose tissue mass and function. SRA is expressed at a higher level in adipose tissue than other organs in wild type mice. SRA−/− mice are resistant to high fat diet-induced obesity, with decreased fat mass and increased lean content. This lean phenotype of SRA−/− mice is associated with decreased expression of a subset of adipocyte marker genes and reduced plasma TNFα levels. The SRA−/− mice are more insulin sensitive, as evidenced by reduced fasting insulin, and lower blood glucoses in response to IP glucose and insulin. In addition, the livers of SRA−/− mice have fewer lipid droplets after high fat diet feeding, and the expression of adipogenesis-associated genes is decreased. To our knowledge, these data are the first to indicate a functional role for SRA in adipose tissue biology in vivo.

Obesity results from an imbalance between energy intake and expenditure, in which the excess energy is stored as triglyceride in white adipose tissue (WAT) with both increased fat cell size (hypertrophy) and number (hyperplasia) (1). Obesity induces a state of chronic, low grade inflammation in fat that is accompanied by the local secretion of cytokines and chemokines attenuating insulin action (2, 3). Recent genetic, cellular, and biochemical studies have identified a molecular network controlling the differentiation of WAT that involves a transcriptional cascade and epigenetic program beginning with CCAAT/enhancer-binding protein β (C/EBPβ) and δ (C/EBPδ) and the glucocorticoid receptor, which induce C/EBPα and peroxisome proliferator-activated receptor γ (PPARγ), the major transcriptional regulators of adipose differentiation (4–9). In addition, adipogenesis is regulated positively by a number of growth factors and hormones including insulin, insulin-like growth factor 1, and the bone morphogenetic proteins, and negatively by Wnt signaling (10, 11).

Long non-coding RNAs (lncRNAs) are non-coding transcripts that have recently emerged as important regulators in diverse biological processes (12, 13) including stem cell pluripotency, embryogenesis, and cellular differentiation. However, the function of lncRNAs in adipogenesis remains to be elucidated. The steroid receptor RNA activator (SRA) was initially characterized as a lncRNA that functions as an RNA coactivator to enhance steroid receptor-dependent gene expression (14). Our and other subsequent studies demonstrated that SRA also functions as an RNA coactivator for non-steroid nuclear receptors (15, 16) and the myogenic differentiation factor MyoD (17). The Sra1 gene also produces an alternative transcript that encodes a protein denoted SRAP (18, 19), although the function of SRAP is largely unknown. Although SRA has been implicated to play a role in myogenesis (17, 20), steroidogenesis (21), breast tumorigenesis (22–24), and cardiomyopathy (25), the lack of a loss-of-function mouse model has limited our understanding of the in vivo biology of SRA.

We have recently shown that SRA promotes adipocyte differentiation and improves insulin-stimulated glucose uptake in adipocytes in vitro through multiple mechanisms, such as coactivating the transcriptional activity of PPARγ, promoting S-phase entry during mitotic clonal expansion, increasing phosphorylation of Akt/protein kinase B and forkhead box protein O1 (FOXO1) in response to insulin, and inhibiting expression of adipocyte-related inflammatory genes (26). To assess

* The abbreviations used are: WAT, white adipose tissue; C/EBP, CCAAT/enhancer-binding protein; PPARγ, peroxisome proliferator-activated receptor γ; SRA, steroid receptor RNA activator; LBM, lean body mass; HFD, high fat diet; qPCR, quantitative PCR; BAT, brown adipose tissue; TG, triglycerol; eWAT, epididymal white fat; DIO, diet-induced obesity; sWAT, subcutaneous white fat; SRC, steroid nuclear receptor coactivators; FM, fat mass; lncRNA, long non-coding RNA; SRAKO, Sra1 gene knock-out.

† This work was supported, in whole or in part, by National Institutes of Health Grant R01DK62876 (to O. A. M.), a Pilot and Feasibility Grant (to B. X.) from the Michigan Diabetes Research Center, and NIH Grant P30DK020572 to the Chemistry Core of the Michigan Diabetes Research Center.

‡ To whom correspondence may be addressed. E-mail: rkoenig@umich.edu.

§ To whom correspondence may be addressed. E-mail: roenig@umich.edu.

¶ To whom correspondence may be addressed. E-mail: sxu@umich.edu.

†‡§ This work was supported, in whole or in part, by National Institutes of Health Grant R01DK62876 (to O. A. M.), a Pilot and Feasibility Grant (to B. X.) from the Michigan Diabetes Research Center, and NIH Grant P30DK020572 to the Chemistry Core of the Michigan Diabetes Research Center.

‡§ This work was supported, in whole or in part, by National Institutes of Health Grant R01DK62876 (to O. A. M.), a Pilot and Feasibility Grant (to B. X.) from the Michigan Diabetes Research Center, and NIH Grant P30DK020572 to the Chemistry Core of the Michigan Diabetes Research Center.

§ This work was supported, in whole or in part, by National Institutes of Health Grant R01DK62876 (to O. A. M.), a Pilot and Feasibility Grant (to B. X.) from the Michigan Diabetes Research Center, and NIH Grant P30DK020572 to the Chemistry Core of the Michigan Diabetes Research Center.
SRA function in vivo, we have generated a whole mouse Sra1 gene knock-out (SRA−/−). In this study, we show that SRA is expressed at higher levels in adipose tissue than other organs. SRA−/− mice are resistant to diet-induced obesity with reduced fat content, decreased expression of subsets of adipocyte genes and inflammation genes, and improved insulin sensitivity. These data indicate an important role for SRA in adipose tissue biology in vivo.

**EXPERIMENTAL PROCEDURES**

**Generation of Sra1 Gene Knock-out (SRA−/−) Mice**—Three mutant ES cell clones generated by gene targeting for mouse Sra1 were obtained from the European Conditional Mouse Mutagenesis Program (EUCOMM). These targeted ES cell clones were generated in the C57BL/6N cell line Jm8.N4 and are heterozygous for wild type Sra1 and Sra1tm1a(EUCOMM)Hengu. For purposes of brevity, mice homozygous for the tm1a allele are referred to as SRA−/−, and heterozygotes for wild type Sra1 are referred to as SRA+/−. The targeting cassette was inserted at position 36828917 of Chromosome 18 upstream of Sra1 exon 3 (the targeting vector is shown in Fig. 2A). The cassette is composed of an FRT site followed by a lacZ sequence and a loxp site. The first loxp site is followed by a neomycin vector, a second FRT site and a second loxp site. A third loxp site is inserted downstream of the targeted exon 3. The critical exon 3 is thus flanked by loxp sites. Although a “conditional ready” (floxed) allele can be created by flp recombinase expression, in the present study the FRT-flanked cassette is left in place, resulting in a functional Sra1 global knockout. Before injection, the ES cells were confirmed to contain the Sra1 mutant gene by long range PCR. In addition, chromosome counting was performed to make sure that the receiving ES cells have at least 50% normal chromosome count. Finally, the ES cell clone HEPD0528_3_F03 with the best long range PCR signal and more than 80% normal chromosome count was microinjected into blastocysts of albino C57BL/6 mice (Jackson Laboratory Stock number 000058) to generate ES cell-mouse chimeras. Twenty-four male chimeras were bred with albino C57BL/6 female mice. Germ line transmission was evaluated by coat color and PCR. Genotyping was determined by LoxP3 site-spanning PCR (forward, 5′-TCCTACAGGAGTTTACACATGTTCCAGGAAAATG; reverse, 5′-ACAGAGCTTGTTTGTTTTCTTC), lacZ PCR (forward, 5′-TTCACTGGCGCTCGTTTTACAACGTCGTGTA; reverse, 5′-ATGTGAGC-GAGTAAACACCGTCGGATTCT), and long range PCR (primers used were as suggested by EUCOMM). Thus, we generated functional Sra1 gene global knock-out mice (ablation of both SRA RNA and SRAP expression), denoted as heterozygous SRA+/− and homozygous SRA−/− (SRAKO) hereafter. The global SRAKO was further confirmed by RT-qPCR for SRA RNA and immunoblot for SRAP (antibody against SRAP was from Bethyl Laboratory, Inc., catalog number A300-742A). F0 germ-line transmitted males were backcrossed with C57BL/6J mice, the resulting F1 SRA−/− mice were intercrossed to derive SRA+/− (wild type, WT), SRA+/− and SRA−/− mice used for phenotype analysis and metabolic studies. Only male mice were studied for the phenotype of SRAKO. Genotyping was carried out by PCR analysis of genomic DNA extracted from the tails of progeny. Animals were housed on a 12-h light and 12-h dark cycle in the Unit for Laboratory Animal Medicine at the University of Michigan, with free access to water and a standard mouse diet; normal chow (9% fat; Lab diet) or a high fat diet (HFD) (60% fat; catalog number D12492, Research Diets, Inc., New Brunswick, NJ). All procedures were approved by the Institutional Animal Care and Use Committee of the University of Michigan.

**Glucose and Insulin Tolerance Tests**—For glucose tolerance tests, mice were subjected to fasting overnight (16 h) and d-glucose (2 g/kg of body weight) was injected intraperitoneally. Blood glucose was monitored at 0, 15, 30, 60, 120, and 180 min after glucose injection. For insulin tolerance tests, mice were subjected to fasting for 6 h and human insulin (1 IU/kg of body weight) was injected intraperitoneally. Blood glucose was monitored at 0, 15, 30, 60, and 120 min after insulin injection.

**Food Intake**—Food intake of normal chow was determined by measuring the remaining food weight weekly for singly housed mice for 6 weeks, and calculated from a 42-day average. At the end point of HFD feeding, the remaining weight of food provided was determined daily in metabolic cages for singly housed mice. Daily food consumption was calculated from a 3-day average.

**Energy Expenditure and Respiratory Quotient**—SRA−− or WT littermate control mice post-HFD were placed in metabolic cages. The University of Michigan Metabolic Phenotyping Core measured oxygen consumption (VO₂), carbon dioxide production (VCO₂), and spontaneous motor activity during 3 consecutive days using the Comprehensive Laboratory Animal Monitoring System (Columbus Instruments), an integrated open-circuit calorimeter equipped with an optical beam activity monitoring system. Values presented are normalized to lean body mass (LBM) plus 20% fat mass (LBM + 0.2FM) to account for the fact that body composition differs between SRA−− and WT mice (27). The respiratory quotient was calculated by dividing the carbon dioxide production by the oxygen consumption. We used the mean values for the light and dark cycles to analyze statistical significance.

**Body Composition**—Body fat, lean body mass, and fluid content in SRA−− mice and WT littermate controls after HFD experiments were measured using nuclear magnetic resonance analysis in The University of Michigan Metabolic Phenotyping Core.

**Histology**—Tissues were fixed in 10% buffered formalin, and histology was assessed by hematoxylin and eosin (H&E) staining at the University of Michigan Cancer Center Research Histology Laboratory.

**Gene Expression Analysis**—Isolated mouse tissues were rinsed in phosphate-buffered saline (PBS), frozen in liquid nitrogen, and stored at −80 °C until extraction. Total RNAs from WAT, brown adipose tissue (BAT), liver and skeletal muscle were isolated using TRIzol reagent followed by treatment with DNase I (Qiagen). RT-qPCR analysis of gene expression was as described previously (21, 26). Primers are listed in Table 1. To determine whether SRA expression is induced by high fat diet feeding, samples of inguinal WAT from male C57BL/6J mice were provided by Dr. Cliff Rosen (Maine Medical Center Research Institute, Scarborough ME). The mice were fed standard chow diet or HFD ad libitum from 3 to 15 weeks of age. The
mice became obese on the HFD with 40% body fat compared with 18% body fat with the normal chow diet, at which point inguinal WAT was isolated for RNA purification as described (28) and subjected to RT-qPCR.

Stromal Vascular Fraction and Adipocyte Isolation—We digested excised epidymal white adipose tissue (eWAT) from 8-week-old male C57BL/6J mice in PBS containing 1% bovine serum albumin (BSA) and 1 mg mL−1 of type II collagenase for 30 min at 37 °C with gentle agitation. The cell suspension was filtered through a 100-μm nitex filter and then centrifuged at 700× g for 5 min to separate floating adipocytes from the stromal vascular fraction pellet. Floating adipocytes were then washed twice with PBS containing 1% BSA. The pellets representing the stromal vascular fraction were collected after each wash.

Blood Chemistry Analysis—Blood samples collected from the tail vein were used to measure blood glucose by a OneTouch Ultra Glucometer. Plasma from mice fasted for 6 h was isolated from whole blood collected into heparinized tubes. Plasma insulin, leptin, TNFα, and IL6 concentrations were measured using luminex technology in a multianalyte panel plate purchased from Millipore in the Chemistry Laboratory of University of Michigan Diabetes Research Center. Plasma adiponectin was determined using a mouse adiponectin radioimmunosay kit from Millipore (catalog number 9271) or Akt (catalog number 9272) obtained from Cell Signaling Technology (Danvers, MA).

RESULTS

SRA Is Highly Expressed in Adipose Tissues—We have shown recently that SRA expression is induced during 3T3-L1 cell adipocyte differentiation in vitro (26). To study SRA function in vivo, we first examined the expression levels of SRA in several murine tissues, and showed that SRA is expressed at the highest level in WAT, followed by BAT (Fig. 1A). Expression of SRA was significantly higher in the adipocyte fraction than in the stromal-vascular fraction of WAT from lean mice (Fig. 1B). In

### TABLE 1

| Gene name | NCBI Ref. Seq. # | Forward primer | Reverse primer |
|-----------|------------------|----------------|----------------|
| Sra1      | NM_025291.3      | GGCCTCAAGGGAAAGATCTCAATAC | TCCACTGTTATGTAATAAGTTCTTG |
| Pparg     | NM_00127330.1    | AGAACAGAGACAGGACAGCATTAC | TATCGATGCTAAGTCTGAGCA |
| Cd36      | NM_00119555.1    | GACACGCAAAAGAAAGAAAGAC | TACCCCTTTTGGTCTGATTC |
| Cd36      | NM_011044.2      | CTTGCCATCTGCTGCTCCCT | TACCCCTTTTGGTCTGATTC |
| Pck1      | NM_008907.1      | TCCAAAGAACAGCAAGAATTCTC | TGGTCTCAGTTCGTCGATAC |
| Cd2       | NM_013333.3      | ATTCAAGTTGAGTTCTGAGGCC | CACAGCTCTCTCTCTCAGTC |
| Adipoq    | NM_009605.4      | AAGAGCAAGACGGCCTTCTCTT | GTGACGCTTGACCATGCGT |
| Tgrp      | NM_001278601.1   | GCACTGCCTGCTGCTGCTGCT | TGGTCTCAGTTCGTCGATAC |
| Il6       | NM_031168.1      | CAGAATGGATGATGTTCTGAG | TGGTCTCAGTTCGTCGATAC |
| Ncoa1     | NM_010881.2      | CATGGCAGGGCAGGAGTAC | GCTCACTGCTGCTGCTGCT |
| Ncoa2     | NM_001076795.1   | AGCTGAGCAAGACGAGAGGAC | TACCCCTTTTGGTCTGATTC |
| Ncoa3     | NM_008679.3      | GAGAGTGCTGCTGCTGCTGCT | TGGTCTCAGTTCGTCGATAC |
| Prdm16    | NM_00177995.1    | ACGCGGAAAGACGAGAGGAC | TACCCCTTTTGGTCTGATTC |
| Cidea     | NM_007702.2      | GCCCTCTACGCCCTGCCAT | ATCCACCCCCGAGACGT |
| Ucp1      | NM_009463.3      | GTGACGCTTGACCATGCGT |
| Cysb      | NM_007751.3      | CACCTCTTCTCTCTCTCTCT | TGGTCTCAGTTCGTCGATAC |
| Ppara     | NM_00113418.1    | CAGGGGTGCTGCTGCTGCTGCT | TGGTCTCAGTTCGTCGATAC |
| Sreb1     | NM_011480.3      | GAAAGATTCCACCGCTGCCAA | TACCCCTTTTGGTCTGATTC |
| Scl1      | NM_000127.4      | GAGAGTGCTGCTGCTGCTGCT | TGGTCTCAGTTCGTCGATAC |
| G6pc      | NM_008601.1      | ACCGCTAAGTGTTCTGAG | TGGTCTCAGTTCGTCGATAC |
| Slc2a1    | NM_031197.2      | CCGCGTACGCCGAGAACGAC | TGGTCTCAGTTCGTCGATAC |
| Pcg1a     | NM_008904.2      | AGAACAGCAGACAGGCTGAGC | TACCCCTTTTGGTCTGATTC |
| Red1p0    | NM_007475.5      | ACCGCGCTGCTGCTGCTGCT | TGGTCTCAGTTCGTCGATAC |
| Tbp       | NM_013684.3      | GCGACAGAGCGCAAGATGQA | TACCCCTTTTGGTCTGATTC |
| Cd137     | NM_001077508.1   | CTGGAGAGACCGGAGCTGAC | TACCCCTTTTGGTCTGATTC |
| Bmp6b     | NM_007559.4      | CTTGAGAGACCGGAGCTGAC | TACCCCTTTTGGTCTGATTC |
| Fndc5     | NM_027402.3      | TCTGAGAGACCGGAGCTGAC | TACCCCTTTTGGTCTGATTC |
| Tbx1      | NM_00285472.1    | CCTAGCTGAGAGACGGAAGGAGC | TACCCCTTTTGGTCTGATTC |
| Tbx15     | NM_009323.2      | TGGAGAGACCGGAGCTGAC | TACCCCTTTTGGTCTGATTC |
addition, SRA expression was significantly induced in WAT from HFD-induced obese mice compared with control mice fed normal chow (Fig. 1C). Consistent with our previous findings that SRA promotes adipogenesis in cell culture (26), these observations suggested that SRA may also play an important role in adipose tissue biology in vivo.

**Generation of Sra1 Gene Knock-out (SRAKO) Mice.**—To directly investigate the role of SRA in adipose tissue in vivo, we have generated SRAKO mice and characterized them with respect to energy and glucose homeostasis. The targeting vector includes a lacZ/neoe cassette with transcription termination signals flanked by FRT sites (Fig. 2A). The cassette was not excised, which is predicted to result in loss of SRA expression and hence a global functional gene knock-out (29).

Five males and four females of the F0 germline transmitted mice were obtained. After backcrossing with C57BL/6J mice, the resulting F1 heterozygous (SRA+/−) mice were intercrossed to derive wild type control (SRA+/-), heterozygous (SRA+/-), and homozygous (SRA−/−) mice, which were confirmed by PCR genotyping (Fig. 2B). The SRA+/- and SRA−/− mice appeared normal. The genotypes of 233 F1 pups obtained at weaning stage included 50 SRA+/-, 120 SRA+/-, and 63 SRA−/− mice, which nearly matched the expected 1:2:1 Mendelian ratio.

SRA RNA expression was assessed in WAT, BAT, liver, and skeletal muscle by RT-qPCR (Fig. 2C, upper panel). SRA RNA expression was reduced ~50% in SRA+/- mice and was absent in SRA−/− mice. Similar results were obtained for the SRA protein (SRAP), assessed by Western blot (Fig. 2C, lower panel). These results confirm successful knock-out of SRA and SRAP expression.

**SRA−/− Mice Are Protected against Diet-induced Obesity (DIO) and Have Decreased Expression of Adipocyte Genes.**—The SRA−/− mice were without significant body weight changes at the age of weaning (3 weeks) and during postweaning 3–6 weeks when fed a normal chow diet (Fig. 3A). At age 6 weeks the SRA−/− and WT littermate control (SRA+/-) mice were placed on a HFD. After 14 weeks on this diet, SRA−/− mice weighed 6 g less than the WT controls, indicating the SRA−/− mice are resistant to diet-induced obesity (Fig. 3A). Characterization of body composition revealed that the differences in total body weight were due to reduced % fat mass, with increased % lean mass in SRA−/− mice (Fig. 3B). As expected from these results, the SRA−/− mice had reduced epididymal white fat (eWAT) and subcutaneous white fat (sWAT) mass (Fig. 3C). Interestingly, SRA−/− mice also had reduced liver mass (Fig. 3D). The reduced fat mass in SRA−/− mice was associated with small adipocytes in eWAT compared with WT mice (Fig. 3F).

We have recently shown that SRA promotes adipocyte differentiation in vitro at least in part through coactivating the transcriptional activity of PPARγ, the master regulator of adipogenesis (26). Consistent with this, in addition to having a decreased amount of WAT, the SRA−/− mice also had reduced expression or a trend toward reduced expression of the adipocyte genes fatty acid-binding protein 4 (Fabp4), and adiponectin (Adipoq) in the sWAT (Fig. 3G) and eWAT (Fig. 3F). In contrast, SRA−/− mice had a trend toward increased eWAT expression of phosphoenolpyruvate carboxykinase 1 (Pck1), an enzyme that regulates the balance between free fatty acids and triglycerides in adipose tissue (Fig. 3F).

In addition, SRA−/− mice had reduced eWAT expression of the inflammation genes tumor necrosis factor α (Tnf) and chemokine (C-C motif) ligand 2 (Ccl2) (also known as MCP-1), and a trend to reduced interleukin 6 (Il6) (Fig. 3F). This is important because diet-induced obesity is known to be a state of increased inflammation (30). Steroid nuclear receptor coactivators (SRCs), which include Ncoa1 (SRC1), Ncoa2 (SRC2), and Ncoa3 (SRC3), are implicated in the control metabolism. SRC1−/− mice are prone to, but SRC2−/− and SRC3−/− mice are protected against, diet-induced obesity (31, 32). As shown in Fig. 3F, the expression of all three SRC genes is unchanged in the SRA−/− mice, suggesting that expression of these genes is neither dependent on SRA nor altered in an attempt to compensate for the loss of SRA.
In addition to the classical and constitutive BAT located in the interscapular region of mice, recent studies have revealed a recruitable BAT that resides within WAT, which has alternatively been called beige, brite, or inducible BAT (33–36). Beige adipocytes are most abundant in the inguinal WAT, a major subcutaneous fat depot in rodents (37). Brown and beige adipocytes express high levels of *Ucp1* and other thermogenic genes (34, 36), and therefore have the potential to counteract obesity and type 2 diabetes. Because increased activities of brown and beige adipocytes have been linked to obesity resistance in many mouse models (38), we assessed the expression of beige adipocyte genes in the sWAT of SRA−/− mice under HFD feeding. Overall, we did not find strong evidence of sWAT browning. The sWAT of SRA−/− mice showed decreased expression of the brown adipocyte marker PR domain-containing protein 16 (*Pram16*), and no change in the expression of *Ucp1* or *CD137*, a beige adipocyte cell surface marker (36) (Fig. 3G). However, SRA−/− mice under HFD feeding did have increased sWAT expression of *Fndc5* (Irisin), which has recently been shown to stimulate *Ucp-1* expression in white adipocytes in culture and increase energy expenditure in mice (39). In addition, there was a trend of increased expression of *Bmp8b*, which has the capacity to increase energy dissipation in BAT (40), and of the beige adipocyte marker *Thbx1* (36, 41), but not of *Thbx15*.

Furthermore, SRA−/− mice also had reduced interscapular BAT mass with reduced brown adipocyte size (Fig. 4, A and B). The expression levels of several BAT genes within the SRA−/− BAT were similar to those in WT mice (Fig. 4C).

**Energy Expenditure Is Unchanged in SRA−/− Mice**—Because adiposity is determined by the balance of calorie intake and utilization, we investigated parameters of energy homeostasis in SRA−/− and WT control mice. In considering the contributions of both LBM and fat mass (FM), we normalized oxygen consumption and carbon dioxide production to LBM plus 20% FM (LBM + 0.2FM), as this has been shown to be a more accurate way to account for variations in FM than simple normalization to LBM or total body weight (27). Upon this analysis, oxygen consumption and respiratory quotient were not significantly changed in SRA−/− mice compared with the WT control mice (Fig. 5, A and B). Furthermore, the absolute food intake of SRA−/− mice from a 42-day average was unaltered on a normal chow diet (data not shown) and during HFD feeding (Fig. 5, A and B). In addition, the total locomotor activity was also unchanged between the two groups (Fig. 5, A and B) during HFD feeding. These experiments suggest that the lean phenotype of SRA−/− mice does not result from changes of caloric intake and energy expenditure. However, as will be discussed below, it is possible that changes in these parameters were too subtle to detect.

**SRA−/− Mice Have Improved Insulin Sensitivity and Decreased Liver Fat**—Consistent with the reduced fat mass with HFD feeding, SRA−/− mice had significantly reduced insulin levels with no change in fasting blood glucose compared with the WT control mice (Fig. 6A). In addition, there was a trend toward lower plasma leptin, and no change in plasma adiponectin, TG, or free fatty acid levels. Furthermore, HFD-fed SRA−/− mice had improved glucose tolerance following intraperitoneal glucose challenge relative to HFD-fed WT mice (Fig. 6B), as well as...
SRA Deficiency Protects against Diet-induced Obesity

The proinflammatory cytokine TNFα is produced in adipose tissue and is elevated in obesity and correlates with insulin resistance (42). SRA−/− mice had reduced plasma TNFα levels, but unchanged levels of IL6, another inflammatory cytokine correlated with insulin resistance (43) (Fig. 6E).

In humans, as a hallmark of the metabolic syndrome, fatty liver is tightly associated with insulin resistance and type 2 diabetes (44). SRA is well expressed in the liver (Fig. 1). Interestingly, SRA−/− mice had a 30% reduction in liver weight compared with WT controls after HFD feeding (Fig. 5D). Strikingly, in contrast to the large lipid droplets that were apparent by H&E staining in the livers from WT mice, lipid droplets were greatly reduced in the livers of SRA−/− mice (Fig. 7A). Further investigation revealed that liver triglyceride and free fatty acid levels were 61 and 54% lower in SRA−/− mice than WT controls with HFD feeding, respectively (Fig. 7, B and C). To further investigate this protection from hepatosteatosis, we analyzed the expression of key lipogenic and metabolic genes in the livers of HFD-fed SRA−/− and WT mice. As shown in Fig. 7D, the expression of Ppara, Pparg, Fabp4, and hormone-sensitive lipase (Lipe) was significantly reduced in the livers of SRA−/− mice, with a trend toward reduced expression of stearoyl-coenzyme A desaturase 1 (Scd1) (p = 0.051). These data suggest that the decreased fatty liver in SRA−/− mice may contribute to the improved insulin sensitivity. However, the expression of several genes involved in hepatic gluconeogenesis and glycolysis was not significantly changed.

DISCUSSION

We have previously shown that overexpression of the IncRNA SRA in ST2 mesenchymal precursor cells promotes their differentiation into adipocytes, and that knockdown of endogenous SRA inhibits 3T3-L1 cell differentiation into adipocytes (26). Here we demonstrate an important role for SRA in adipocyte biology in mice in vivo. To our knowledge, this is the first report for an IncRNA playing a role in the regulation of fat mass in vivo. We found that SRA is expressed at a much higher level in adipose tissue than other mouse organs. Also, SRA is induced in WAT in mice under HFD feeding. Global knock-out of SRA protects against diet-induced obesity and improves whole body glucose homeostasis. These results are consistent with in vitro data showing that SRA can function as a PPARγ coactivator. We cannot rule out the potential coactivation by SRA of other transcription factors that may play roles in adipogenesis. For example, SRA can promote glucocorticoid receptor-mediated transactivation (14), and recently the glucocorticoid receptor has been shown to play an important role regulating early adipogenesis (7). In addition, our microarray data reveal hundreds of SRA-responsive genes in adipocyte cell lines in culture, including genes related to cell cycle, insulin, and TNFα signaling (26). Although many of these SRA-mediated changes are likely indirect, a substantial fraction may be direct given that SRA is a transcriptional coregulator. Thus, the contribution of SRA to adipogenesis in vivo may be complex and through multiple pathways.

The mechanism of transcriptional coactivation by SRA is not resolved, but SRA exists in a ribonucleoprotein complex and may play roles in adipogenesis. For example, SRA can function as a PPARγ coactivator. We cannot exclude the possibility that SRA is a transcriptional coregulator. Thus, the expression of SRA and SRA is expressed at a much higher level in adipose tissue than other mouse organs. Also, SRA is induced in WAT in mice under HFD feeding. Global knock-out of SRA protects against diet-induced obesity and improves whole body glucose homeostasis. These results are consistent with in vitro data showing that SRA can function as a PPARγ coactivator. We cannot rule out the potential coactivation by SRA of other transcription factors that may play roles in adipogenesis. For example, SRA can promote glucocorticoid receptor-mediated transactivation (14), and recently the glucocorticoid receptor has been shown to play an important role regulating early adipogenesis (7). In addition, our microarray data reveal hundreds of SRA-responsive genes in adipocyte cell lines in culture, including genes related to cell cycle, insulin, and TNFα signaling (26). Although many of these SRA-mediated changes are likely indirect, a substantial fraction may be direct given that SRA is a transcriptional coregulator. Thus, the contribution of SRA to adipogenesis in vivo may be complex and through multiple pathways.

The mechanism of transcriptional coactivation by SRA is not resolved, but SRA exists in a ribonucleoprotein complex and may serve as a scaffold to recruit coactivator proteins to target genes. In addition, IncRNAs can bind to DNA to form a RNA:DNA triplex (45), which has been proposed to recruit IncRNA-binding proteins to DNA (46). The Sra1 gene is unusual in that it expresses both an IncRNA (SRA) and a protein (SRAP) by alternative splicing (18, 19). Based upon cell culture experiments with the non-coding SRA RNA (26), it is most likely that this IncRNA exerts the major adipogenic effects observed here. However, because the mouse knock-out abolishes expression of both SRA and SRAP, we cannot exclude a possible role of SRAP in adipocytes.

SRA−/− mice under HFD feeding demonstrate reduced adiposity with decreased percent of body fat and increased percent of lean mass (Fig. 3). This observation is further evidenced by reduced epididymal and subcutaneous WAT mass, reduced BAT mass, and decreased expression of several WAT marker genes (Fig. 3). Recent studies indicate that “brown-like” cells exist in subcutaneous WAT, called beige cells or brite cells (34, 36, 47, 48). The activities of both classical brown and beige fat...
cells reduce obesity in mice and correlate with leanness in human (38, 49). However, SRA KO mice did not have a generalized increase in beige cell markers within WAT at the end of the HFD feeding. Overall, these data suggest that the reduced adiposity in these mice is not due to increased activity of BAT and beige fat cells.

Our data indicate that SRAKO in mice improves whole body insulin sensitivity when fed a HFD (Fig. 6, B and C). This effect also is manifest at a molecular level, because the SRA KO mice show increased phosphorylation of Akt in WAT, liver, and muscle in response to acute insulin challenge (Fig. 6D). Because these mice have decreased fat mass, the simplest explanation...
FIGURE 6. **SRAKO improves DIO-induced insulin resistance.** A, plasma hormone levels in SRA−/− mice were analyzed and compared with WT controls. All data in this figure were measured at the end of DIO. Blood glucose, plasma TG, and free fatty acid (non-esterified fatty acid) levels were measured at fasting conditions (6 h), n = 6–7. B, glucose tolerance test (GTT) at the end of DIO. Mice were fasted overnight (16 h), and a standard glucose tolerance test was performed. C, insulin tolerance test (ITT) at the end point of DIO. Mice were fasted overnight (16 h), and a standard insulin tolerance test was performed, n = 6–7 mice. D, SRAKO enhances insulin-stimulated phosphorylation of Akt under HFD feeding. HFD-fed SRA−/− and WT control mice were fasted overnight (16 h). Five minutes after PBS or insulin injection via tail vein, epididymal WAT, liver, and gastrocnemius muscles were dissected. The tissue lysates were immunoblotted for pAkt (Ser-473) and total Akt. E, plasma TNFα and IL6 levels were analyzed as described for panel A. *, p < 0.05; **, p < 0.01; IB, immunoblot.

FIGURE 7. **SRAKO inhibits the formation of fatty liver under HFD.** A, H&E sections of liver at the end point of DIO. B and C, liver TG and non-esterified fatty acid levels were analyzed, respectively, n = 6–7. D, RT-qPCR analysis of expression of liver genes involved in lipogenesis, gluconeogenesis, and glycolysis. Data were normalized to Ppia mRNA and relative to the expression of each gene in WT mice, n = 6–7. *, p < 0.05 and **, p < 0.01.

SRA Deficiency Protects against Diet-induced Obesity
SRA Deficiency Protects against Diet-induced Obesity

for the improved insulin sensitivity is a direct effect of loss of SRA on adipogenesis and adipocyte function, probably at least in part through decreased PPARy function. However, these mice have a global loss of SRA, and therefore other tissues may contribute to improved whole body insulin sensitivity. For example, SRA is expressed at significant levels in liver, and SRAKO mice have decreased hepatic steatosis. Whether the loss of hepatocyte SRA is a factor in this remains to be determined.

Furthermore, it is well recognized that chronic tissue inflammation is an important cause of obesity-induced insulin resistance (3, 50). One example of evidence for this relationship is that the cytokine TNFα is elevated in the adipose tissue of obese rodents and inhibition of this cytokine improves glucose tolerance and insulin sensitivity (42). Importantly, compared with WT control mice, SRA−/− mice have significantly reduced expression of a subset of inflammation genes including Tnf (TNFα) and Ccl2 (MCP-1) in WAT (Fig. 3F) and decreased plasma TNFα levels (Fig. 6E). These results suggest that reduced inflammatory signaling may contribute significantly to the improved insulin sensitivity in SRA−/− mice. Because SRA is expressed at a relatively high level in mouse spleen (Fig. 1), as well as in monocytes derived from mouse spleen and murine macrophage J774A.1 cells (data not shown), SRAKO may have direct anti-inflammatory effects on the immune system.

It is at first glance puzzling that SRA−/− mice are protected from diet-induced obesity, yet there is no detectable change in food intake or energy expenditure. Perhaps they are inefficient at absorbing food from the gut, which could be an effect of SRAKO in the mouse itself or a secondary effect on the gut microbiome (51, 52). It also is possible that changes in energy expenditure or food intake went undetected because they are too subtle. For example, it has been calculated that for mice to gain an excess of 10 g over 25 weeks (a rate of change almost identical to that observed in this study), an energy imbalance of only ~3% is required (27). Detecting a 2.5% change in energy intake with 80% power would require a sample size of 350 mice (53), and detecting the expected changes would be even more daunting if the underlying basis is multifactorial.

In summary, the current studies, which are the first report of an in vivo SRA knock-out, demonstrate an important role for SRA in the regulation of adipose tissue mass, fatty liver, glucose homeostasis, and metabolism-related gene expressions in vivo. Future studies using tissue-specific knockouts will help clarify the underlying mechanisms regarding whole animal insulin sensitivity and will shed further light on the biological functions of SRA as a potential target to control obesity and type 2 diabetes.

Acknowledgments—We thank Drs. Martin Myers and Liangyou Rui for helpful discussions. The mouse metabolic studies were performed by the University of Michigan Nutrition Obesity Research Center (P30DK089503).

REFERENCES

1. Gesta, S., Tseng, Y. H., and Kahn, C. R. (2007) Developmental origin of fat: tracking obesity to its source. Cell 131, 242–256
2. Doria, A., Patti, M. E., and Kahn, C. R. (2008) The emerging genetic architec-
SRA Deficiency Protects against Diet-induced Obesity

16081–16086
23. Leygue, E., Dotzlau, H., Watson, P. H., and Murphy, L. C. (1999) Expression of the steroid receptor RNA activator in human breast tumors. Cancer Res. 59, 4190–4193
24. Murphy, L. C., Simon, S. L., Parkes, A., Leygue, E., Dotzlau, H., Snell, L., Troup, S., Adeyinka, A., and Watson, P. H. (2000) Altered expression of estrogen receptor coregulators during human breast tumorigenesis. Cancer Res. 60, 6266–6271
25. Friederichs, F., Zugck, C., Rauch, G. J., Ivanidic, B., Weichenhan, D., Müller-Bardorf, M., Meder, B., El Mokhtari, N. E., Regitz-Zagrosek, V., Hetzer, R., Schäfer, A., Schreiber, S., Chen, J., Neuhaus, I. J., Ri, S., Siemens, N. O., Frey, N., Rottbauer, W., Katus, H. A., and Stoll, M. (2009) HBEGF, SRA1, and IK: three coregulating genes as determinants of cardiomyopathy. Genome Res. 19, 395–403
26. Xu, B., Gerin, I., Miao, H., Vu-Phan, D., Johnson, C. N., Xu, R., Chen, X. W., Cawthorn, W. P., MacDougall, O. A., and Koenig, R. J. (2010) Multiple roles for the non-coding RNA SRA in regulation of adipogenesis and insulin sensitivity. PLoS One 5, e114199
27. Even, P. C., and Nadkarni, N. A. (2012) Indirect calorimetry in laboratory mice and rats: principles, practical considerations, interpretation and perspectives. Am. J. Physiol. Regul. Integr. Comp. Physiol. 303, R459–476
28. Du, B., Cawthorn, W. P., Su, A., Doucette, C. R., Yao, Y., Hemati, N., Kampert, S., McCoin, C., Broome, D. T., Rosen, C. J., Yang, G., and MacDougall, O. A. (2013) The transcription factor paired-related homeobox 1 (Prx1) inhibits adipogenesis by activating transforming growth factor-β (TGFβ) signaling. J. Biol. Chem. 288, 3036–3047
29. Skarnes, W. C., Rosen, B., West, A. P., Koutsourakis, M., Bushell, W., Iyer, V., Mujica, A. O., Thomas, M., Harrow, J., Cox, T., Jackson, D., Severin, J., Biggs, P., Fu, J., Nefedov, M., de Jong, P. J., Stewart, A. F., and Bradley, A. (2011) A conditional knockout resource for the genome-wide study of mouse gene function. Nature 474, 337–342
30. Glass, C. K., and Olefsky, J. M. (2012) Inflammation and lipid signaling in the etiology of insulin resistance. Cell Metab. 15, 635–645
31. Coste, A., Louet, J. F., Lagouge, M., Lerin, C., Antal, M. C., Meziane, H., Schoonjans, K., Puigserver, P., O’Malley, B. W., and Auwerx, J. (2008) The genetic ablation of SRC-3 protects against obesity and improves insulin sensitivity by reducing the acetylation of PGC-1α. Proc. Natl. Acad. Sci. U.S.A. 105, 17187–17192
32. Picard, F., Géhin, M., Annicotte, J., Rocchi, S., Champy, M. F., O’Malley, B. W., Chambon, P., and Auwerx, J. (2002) SRC-1 and TIF2 control energy balance between white and brown adipose tissues. J. Biol. Chem. 278, 7153–7164
33. Schulz, T. J., Huang, T. L., Tran, T. T., Zhang, H., Townsend, K. L., Shadrach, J. L., Cerletti, M., MacDougall, L. E., Giorgadze, N., Tchkonia, T., Schrier, D., Falb, D., Kirkland, J. L., Wagers, A. J., and Tseng, Y. H. (2010) Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328, 2203–2205
34. Vijay-Kumar, M., Aitken, J. D., Carvalho, F. A., Cullender, T. C., Mwangi, T. J., Ok, J., Weidmann, F., Serna, B., Gaur, S., He, X., and Stenderup, J. (2011) Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science 328, 2203–2205
35. Argáñaraz, E., Chen, J., Li, Y., Jia, L., Chen, J., and Li, H. (2012) BMP8B increases brown adipose tissue thermogenesis through both central and peripheral actions. Cell 149, 871–885
36. Ludeña, M. G., Gardinoti, A., and Schieber, A. (2012) BMP8B increases brown adipose tissue thermogenesis through both central and peripheral actions. Cell 149, 871–885
37. Schäfer, A., Schreiber, S., Chen, J., Neuhaus, I., Ji, R., Siemers, N. O., Frey, N., Rottbauer, W., Katus, H. A., and Stoll, M. (2009) HBEGF, SRA1, and IK: three coregulating genes as determinants of cardiomyopathy. Genome Res. 19, 395–403
38.rites reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classic brown adipocytes. J. Biol. Chem. 285, 11105–11114